CRM three-lens brief
Evidence-based stock research on CRM. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 14% of its 52-week range — deep in the lower band.
- Trading at 14% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Analyst mean target $245.60 — 49% above current (52 analysts).
CRM closed at $164.80 (+1.42%) as of 2026-07-10. Market cap: $134.97B. P/E (trailing) 19.1. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $245.60 — 49% above current (52 analysts).. Concerns: trading at 14% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $11.13B, net income $2.11B, free cash flow $16.55B.
Why three lenses on CRM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CRMacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CRM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CRM brief"></iframe>